There are strong indications that the HER2-enriched subtype is considered a high-risk entity among DCIS grade 3 cases, as it is significantly associated with the presence of an invasive component in our cohort (p value = 0.0169). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.